Vinge advises Active Biotech in relation to directed new share issue
April 04, 2013
In March this year, Active Biotech AB (publ) conducted a directed new share issue to Investor AB (publ) pursuant to which Active Biotech procured SEK 270 million.
Vinge’s team consisted of partner Erik Sjöman and associate Christian Lindhé.
Vinge has advised Platzer on a combined asset swap transaction with the Port of Gothenburg comprising the sale of the property Arendal 1:28, parts of the properties Arendal 1:29 and Arendal 1:31, and the acquisition of part of the property Arendal 764:291.
Vinge has advised Skandinaviska Enskilda Banken AB (publ), Swedbank AB (publ) and Danske Bank A/S in their capacities as mandated lead arrangers and bookrunners in connection with a term loan bridge facility in an aggregate amount of SEK 4,360,000,000, EUR 195,000,000 and DKK 170,000,000 to Catena AB (publ).
Vinge has advised the founders of Nordic Knots in connection with an investment in the company led by Imaginary Ventures, with additional investors including Creades, IRIS Ventures and St Dominique Capital.
